drugset
drugset / Trial / NCT04997161

Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia

NCT04997161 ↗

Phase 4 Terminated 3 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

Prescribing Sodium zirconium cyclosilicate (SZC) with enhanced nutritional advice to participants with hyperkalaemia on haemodialysis will reduce serum K+ (S-K+ ) and enable the consumption of more fruit and vegetables and more satisfying diet. The study aims to show that participants using SZC achieve S-K+ reduction as well as participants on SoC (other than K+ binders), without the need for restricting K+ in the diet.

Timeline

Start
2021-08-17
Primary completion
2021-11-17
Completion
2021-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Zirconium Cyclosilicate Other / unclassified — —

Indications

No indication recorded.